130 related articles for article (PubMed ID: 1405759)
1. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells.
Steube KG; Grunicke D; Pietsch T; Gignac SM; Pettit GR; Drexler HG
Leukemia; 1992 Oct; 6(10):1048-53. PubMed ID: 1405759
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
3. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
Vrana JA; Saunders AM; Chellappan SP; Grant S
Differentiation; 1998 May; 63(1):33-42. PubMed ID: 9615391
[TBL] [Abstract][Full Text] [Related]
4. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
Beckwith M; Urba WJ; Longo DL
J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
[TBL] [Abstract][Full Text] [Related]
7. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3.
Hu ZB; Ma W; Zaborski M; MacLeod R; Quentmeier H; Drexler HG
Leukemia; 1996 Jun; 10(6):1025-40. PubMed ID: 8667638
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.
Kennedy MJ; Prestigiacomo LJ; Tyler G; May WS; Davidson NE
Cancer Res; 1992 Mar; 52(5):1278-83. PubMed ID: 1737390
[TBL] [Abstract][Full Text] [Related]
10. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression.
Clark CS; Konyer JE; Meckling KA
Exp Cell Res; 2004 Mar; 294(1):301-11. PubMed ID: 14980523
[TBL] [Abstract][Full Text] [Related]
11. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.
Jalava AM; Heikkilä J; Akerlind G; Pettit GR; Akerman KE
Cancer Res; 1990 Jun; 50(11):3422-8. PubMed ID: 2334938
[TBL] [Abstract][Full Text] [Related]
12. Effects of bryostatins and retinoic acid on phorbol ester- and diacylglycerol-induced squamous differentiation in human tracheobronchial epithelial cells.
Jetten AM; George MA; Pettit GR; Rearick JI
Cancer Res; 1989 Jul; 49(14):3990-5. PubMed ID: 2567623
[TBL] [Abstract][Full Text] [Related]
13. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
[TBL] [Abstract][Full Text] [Related]
14. Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.
Hu ZB; Ma W; Uphoff CC; Lanotte M; Drexler HG
Leukemia; 1993 Nov; 7(11):1817-23. PubMed ID: 7901456
[TBL] [Abstract][Full Text] [Related]
15. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
16. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
Ali MA; Rosati R; Pettit GR; Kalemkerian GP
Anticancer Res; 1998; 18(2A):1021-6. PubMed ID: 9615758
[TBL] [Abstract][Full Text] [Related]
17. The role of growth factors in the activity of pharmacological differentiation agents.
Matsui WH; Gladstone DE; Vala MS; Barber JP; Brodsky RA; Smith BD; Jones RJ
Cell Growth Differ; 2002 Jun; 13(6):275-83. PubMed ID: 12114217
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2.
Asiedu C; Biggs J; Lilly M; Kraft AS
Cancer Res; 1995 Sep; 55(17):3716-20. PubMed ID: 7641182
[TBL] [Abstract][Full Text] [Related]
19. Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells.
Sako T; Yuspa SH; Herald CL; Pettit GR; Blumberg PM
Cancer Res; 1987 Oct; 47(20):5445-50. PubMed ID: 2888531
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells.
Dell'Aquila ML; Nguyen HT; Herald CL; Pettit GR; Blumberg PM
Cancer Res; 1987 Nov; 47(22):6006-9. PubMed ID: 3478136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]